Osteonecrosis of the jaw associated with bisphosphonate therapy

Orthopedics

Volumn 32, Issue 12, 2009, Pages 900-

  Wirth, Scott M ^a   Lawson, Amber P ^b   Sutphin, Stephanie D ^b,c   Adams, Val R ^b,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE GLUCONATE; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

AGING; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; BONE DISEASE; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL PRACTICE; DEBRIDEMENT; DENTAL SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG INDICATION; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; MOUTH HYGIENE; MULTIPLE MYELOMA; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; STEROID THERAPY; TOOTH DISEASE; TOOTH EXTRACTION;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW; JAW DISEASES; OSTEONECROSIS; RISK FACTORS;

EID: 75149148738     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20091020-16     Document Type: Review

References (24)

1. Fosamax (alendronate sodium) package insert. Whitehouse Station, NJ: Merck & Co, Inc; 2008.
2. Actonel (risedronate sodium) package insert. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2008.
3. Boniva (ibandronate sodium tablets) package insert. Nutley NJ: Roche Laboratories; 2008.
4. Boniva (ibandronate sodium injection) package insert. Nutley NJ: Roche Laboratories; 2007.
5. Skelid (tiludronate disodium) package insert. Bridgewater, NJ: Sanofi-Aventis; 2006.
6. Reclast (zoledronic acid) package insert. East Hanover, NJ:Novartis; 2008.
7. Zometa (zoledronic acid) package insert. East Hanover, NJ:Novartis; 2008.
8. Didronel (etidronate disodium) package insert. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2007.
9. Aredia (pamidronate disodium) package insert. East Hanover, NJ: Novartis; 2008.
10. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998; 38:375-388.
11. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8(5):1080-1084.
12. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis (published online ahead of print January 18, 2008). Bone. 2008; 42(5):841-847.
13. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management (published online ahead of print July 31, 2006). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4):433-441.
14. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-376.
15. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24(6):945-952.
16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23(34):8580-8587.
17. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients (published online August 1, 2006). Br J Haematol. 2006; 134(6):620-623.
18. King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy. 2008; 28(5):667-677.
19. Sung EC, Chan SM, Sakurai K, Chung E. Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist. 2002; 22(4):142-146.
20. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-1491.
21. Kyle RA, Yee GC, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007; 25(17):2464-2472.
22. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid (published online ahead of print Jun 1, 2006). Haematologica. 2006; 91(7):968-971.
23. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006; 137(8):1144-1150.
24. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006; 81(8):1047-1053.